<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943136</url>
  </required_header>
  <id_info>
    <org_study_id>Papaya for impetigo</org_study_id>
    <nct_id>NCT01943136</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippine Dermatological Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Luke's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philippine Dermatological Society</source>
  <brief_summary>
    <textblock>
      This study will be an investigator-blinded, patient-blinded, assessor-blinded,
      parallel-group, randomized clinical trial. It aims to evaluate the efficacy of one-week
      twice-daily application of topical papaya leaf extract ointment compared to mupirocin
      ointment in achieving clinical cure among patients with impetigo.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical clearance after 1 week of treatment</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to clinical clearance</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score in the 6-point grading system</measure>
    <time_frame>1 week</time_frame>
    <description>The 6-point grading system will assess clinical response based on each of the following six paramaters. One point will be assigned for each of the following parameters present in a patient, with the maximum possible score on this grading system being 6. A patient need not satisfy all six parameters. A decrease in score on this grading system compared to baseline will indicate clinical improvement, while an increase in score will indicate clinical worsening.
erythema
edema
vesiculation
pustulation
crusting
scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in size of lesion compared to baseline</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or absence of recurrence on any part of the body 2 weeks after starting treatment</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or absence of adverse events during treatment</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>papaya 1% extract ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>papaya 1% extract ointment twice a day for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mupirocin 2% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mupirocin 2% ointment twice a day for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>papaya 1% extract ointment</intervention_name>
    <arm_group_label>papaya 1% extract ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mupirocin 2% ointment</intervention_name>
    <arm_group_label>mupirocin 2% ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Filipino patients aged 1 year and above with primary impetigo, limited to less
             than or equal to 1% BSA, and involving only one body area

        Exclusion Criteria:

          -  Extensive impetigo (&gt;1% BSA), affecting more than one body area

          -  Systemic involvement (lymphadenopathy, fever, sepsis)

          -  Chronic comorbidities like diabetes mellitus, malignancy, chronic venous insufficiency

          -  Concurrent immunosuppressive therapy

          -  Patients ≤ 1 year

          -  Pregnant &amp; lactating patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mia Angela C Verzosa, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pearl Weena Marie E Sabido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janine L. Quijano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janine L. Quijano, MD</last_name>
    <email>janinequijanoMD@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>NCR</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quijano</last_name>
      <email>janinequijanoMD@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <reference>
    <citation>Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2012 Jan 18;1:CD003261. doi: 10.1002/14651858.CD003261.pub3. Review.</citation>
    <PMID>22258953</PMID>
  </reference>
  <reference>
    <citation>Craft N, Lee PK, Zipoli MT, Weinberg AN, Swartz MN, Johnson RA. &quot;Superficial cutaneous infections and pyodermas.&quot; Ftizpatrick's Dermatology in General Medicine, 7th ed. Ed. Wolff K, et al. USA: McGraw-Hill Companies, 2008. 1694-1709.</citation>
  </reference>
  <reference>
    <citation>Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect. 2009 Sep;59 Suppl 1:S4-16. doi: 10.1016/S0163-4453(09)60003-7. Review.</citation>
    <PMID>19766888</PMID>
  </reference>
  <reference>
    <citation>Witte W, Cuny C, Klare I, Nübel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol. 2008 Jul;298(5-6):365-77. doi: 10.1016/j.ijmm.2007.10.005. Epub 2008 Mar 5. Review.</citation>
    <PMID>18325835</PMID>
  </reference>
  <reference>
    <citation>Pineda-Rebong AM, Tan JGB. Comparison of 2% oxytetracycline ointment with 2% mupirocin ointment and 2% sodium fusidate ointment in the treatment of impetigo in children: a preliminary report. J Phil Dermatol Soc 2011 May;20(1):21-4.</citation>
  </reference>
  <reference>
    <citation>Martin KW, Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother. 2003 Feb;51(2):241-6. Review.</citation>
    <PMID>12562687</PMID>
  </reference>
  <reference>
    <citation>Anibijuwon II, Udeze AO. Antimicrobial activity of Carica papaya (pawpaw) leaf on some pathogenic organisms of clinical origin from south-western Nigeria. Ethnobotanical Leaflets 2009;13:850-64.</citation>
  </reference>
  <reference>
    <citation>Pieper B, Caliri MH. Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids. J Wound Ostomy Continence Nurs. 2003 Jul;30(4):175-83. Review.</citation>
    <PMID>12851592</PMID>
  </reference>
  <reference>
    <citation>Hewitt H, Whittle S, Lopez S, Bailey E, Weaver S. Topical use of papaya in chronic skin ulcer therapy in Jamaica. West Indian Med J. 2000 Mar;49(1):32-3.</citation>
    <PMID>10786448</PMID>
  </reference>
  <reference>
    <citation>Owoyele BV, Adebukola OM, Funmilayo AA, Soladoye AO. Anti-inflammatory activities of ethanolic extract of Carica papaya leaves. Inflammopharmacology. 2008 Aug;16(4):168-73. doi: 10.1007/s10787-008-7008-0.</citation>
    <PMID>18759075</PMID>
  </reference>
  <reference>
    <citation>Mahmood AA, Sihdik K, Salmah I. Wound healing activity of Carica papaya L. aqueous leaf extracts in rats. International Journal of Molecular Medicine and Advance Sciences 2005;1(4):398-401.</citation>
  </reference>
  <reference>
    <citation>Buensalido JS, Dimagiba TE. The efficacy and safety of 1.5% carica papaya latex cream compared to 2% ketoconazole cream and vehicle in the treatment of tinea corporis: A randomized, double blind, controlled trial. J Phil Dermatol Soc 2011 May;20(1):15-20.</citation>
  </reference>
  <reference>
    <citation>Canoy-Valencia H, King-Joanino SVB. An in vitro study of the therapeutic effects of Carica papaya against superficial pyodermas. Makati Medical Center Proceedings 1996;10:21-3.</citation>
  </reference>
  <reference>
    <citation>Ablang AMJ, Nuguid AS. In vitro activity of Carica papaya powdered extract alone and in combination with penicillin against clinical isolates of Streptococcus pyogenes. Makati Medical Center Proceedings 2000;14:11-5.</citation>
  </reference>
  <reference>
    <citation>Dawkins G, Hewitt H, Wint Y, Obiefuna PC, Wint B. Antibacterial effects of Carica papaya fruit on common wound organisms. West Indian Med J. 2003 Dec;52(4):290-2.</citation>
    <PMID>15040064</PMID>
  </reference>
  <reference>
    <citation>Doughari JH, Elmahmood AM, Manzara S. Studies on the antibacterial activity of root extracts of Carica papaya L. African Journal of Microbiology Research 2007 August:37-41.</citation>
  </reference>
  <reference>
    <citation>Okechukwu RI, Obasi KO, Nnoli MC, Ukaoma AA. Antimicrobial properties and preliminary phytochemical analysis of Carica papaya leaf. Advances in Science and Technology 2010;4(1):45-8.</citation>
  </reference>
  <reference>
    <citation>Suresh K, Deepa P, Harisaranraj R, Achudhan V. Antimicrobial and phytochemical investication of the Carica papaya L., Cynodon dactylon (L.) Pers., Euphorbia herta L. Melia azedarach L., and Psidium guajava L. Ethnobotanical Leaflets 2008;12:1184-91.</citation>
  </reference>
  <reference>
    <citation>Celis MA, Verallo-Rowell VM. Carica papaya versus Fucidin cream in the treatment of superficial pyodermas in pediatric patients: A double blind study. (Unpublished, 1996).</citation>
  </reference>
  <reference>
    <citation>Oduola T, Adeniyi FAA, Ogunyemi EO, Bello IS, Idowu TO, Subair HG. Toxicity studies on an unripe Carica papaya aqueous extract: biochemical and haematological effects in wistar albino rats. Journal of Medicinal Plants Research 2007 August;1(1):1-4.</citation>
  </reference>
  <reference>
    <citation>Iliev D, Elsner P. Generalized drug reaction due to papaya juice in throat lozenges. Dermatology. 1997;194(4):364-6.</citation>
    <PMID>9252760</PMID>
  </reference>
  <reference>
    <citation>Niinimäki A, Reijula K, Pirilä T, Koistinen AM. Papain-induced allergic rhinoconjunctivitis in a cosmetologist. J Allergy Clin Immunol. 1993 Sep;92(3):492-3.</citation>
    <PMID>8360400</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philippine Dermatological Society</investigator_affiliation>
    <investigator_full_name>Pearl Weena Marie Sabido</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>impetigo</keyword>
  <keyword>papaya extract ointment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

